Prostate Cancer

Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis

Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis

By

The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.

GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible

GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible

By

A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.

Immunotherapy and the Future of Prostate Cancer Treatment

Immunotherapy and the Future of Prostate Cancer Treatment

By

Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.

Targeting AR Mutations Promising in Metastatic Prostate Cancer

Targeting AR Mutations Promising in Metastatic Prostate Cancer

By

A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.

Adding Bicalutamide to Salvage RT Improves OS in Recurrent Prostate Cancer

Adding Bicalutamide to Salvage RT Improves OS in Recurrent Prostate Cancer

By

Investigators studied the effects of adding antiandrogen therapy to radiotherapy on cancer control and overall survival in men with prostate cancer recurrence after radical prostatectomy.

Clinicians May Want To Address Emotional Stress to Prevent Overtreatment of Localized Prostate Cancer

Clinicians May Want To Address Emotional Stress to Prevent Overtreatment of Localized Prostate Cancer

By

Some men with low-risk prostate cancer may opt for more aggressive treatments due to emotional distress.

Prostate Cancer Treatment Rates Decrease Following Changes in Treatment Recommendations

Prostate Cancer Treatment Rates Decrease Following Changes in Treatment Recommendations

By

The implementation of recommendations opposing regular prostate cancer screening appear to have lowered treatment rates dramatically.

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

By

Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.

Hormone Therapy for Prostate Cancer (Fact Sheet)

Hormone Therapy for Prostate Cancer (Fact Sheet)

This fact reviews how hormone therapy may be used to treat prostate cancer, treatment options for castration-resistant prostate cancer, and side effects of hormone therapy.

Less Intense Surveillance Acceptable for Some Prostate Cancer Cases

Less Intense Surveillance Acceptable for Some Prostate Cancer Cases

Patients on active surveillance with stable disease may be candidates for less intense surveillance

Most Common Reason for Prostate Cancer Second Opinions: More Information

Most Common Reason for Prostate Cancer Second Opinions: More Information

By

Although many men obtain a second opinion regarding their prostate cancer care options, they seldom deviate from the original course of action.

MRI Plays a Role After Negative Prostate Biopsy

MRI Plays a Role After Negative Prostate Biopsy

Magnetic resonance imaging and MRI-targeted biopsy can facilitate detection of clinically significant prostate disease.

Cognitive Therapy Not More Effective Than Usual Care for Distress Reduction in Advanced PCa

Cognitive Therapy Not More Effective Than Usual Care for Distress Reduction in Advanced PCa

By

Advanced prostate cancer is associated with substantial psychosocial morbidity; therefore, this study was conducted to evaluate whether mindfulness-based cognitive therapy reduces distress in this population.

Guidelines Issued for Prostate MRI After Negative Biopsy

Guidelines Issued for Prostate MRI After Negative Biopsy

Consensus statement presents guidelines for prostate magnetic resonance imaging (MRI) in patients with negative biopsy.

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

[Clinical Medicine Insights: Oncology] This research examines the various mechanisms of resistance to chemotherapy in metastatic CRPC and the potential role of emerging regimens and agents in varying clinical phases of development.

Cancer Patients Benefit From Exercise Both During and After Treatment

Cancer Patients Benefit From Exercise Both During and After Treatment

Studies show better physical function and quality of life for cancer patients who do strength training or aerobic activity.

Second Opinions Rarely Change Prostate Cancer Decisions

Second Opinions Rarely Change Prostate Cancer Decisions

The impact of additional opinions on patient decision-making is limited.

Study Shows Effects of 2012 USPSTF Recommendation Against PSA Screening

Study Shows Effects of 2012 USPSTF Recommendation Against PSA Screening

By

Researchers report on their evaluation of the impact of the 2012 USPSTF recommendation on volumes of prostate biopsy and radical prostatectomy.

Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered

Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered

By

Researchers analyzed data from the NPCR of Sweden to determine whether more US men with prostate cancer would choose active surveillance if it were presented as a treatment option.

Androgen Deprivation Therapy for Prostate Cancer May Increase Dementia Risk

Androgen Deprivation Therapy for Prostate Cancer May Increase Dementia Risk

By

Growing evidence suggests a link between androgen deprivation therapy (ADT) and cognitive dysfunction, but whether it may contribute to the risk of dementia more broadly is unclear. In this study, researchers examined the association of ADT with subsequent development of dementia in patients with prostate cancer.

Early Post-op RT Linked to Worse Functional Outcomes in Prostate Cancer

Early Post-op RT Linked to Worse Functional Outcomes in Prostate Cancer

By

Radiotherapy administered postoperatively within 1 year of radical prostatectomy was associated with worse functional outcomes compared with radiotherapy administered 1 year or more after surgery.

E-HF Radiation Therapy Side Effects Comparable to CF Radiation Therapy in Prostate Cancer

E-HF Radiation Therapy Side Effects Comparable to CF Radiation Therapy in Prostate Cancer

By

Side effects experienced with extremely hypofractionated treatment for intermediate-risk prostate cancer were comparable to those of conventional radiation therapy at 2 years after treatment.

Postdiagnosis Physical Activity Linked to Improved Physical QoL in Prostate Cancer Survivors

Postdiagnosis Physical Activity Linked to Improved Physical QoL in Prostate Cancer Survivors

By

Prostate cancer survivors who maintain or begin recreational physical activity following cancer diagnosis report substantially higher quality of life than those who never exercise or stopped exercising after diagnosis.

Disease-Specific Mortality Comparable Among Treatment Options for Prostate Cancer

By

Disease-specific mortality rates for men with prostate cancer are comparable for 3 treatment options: active surveillance, radical prostatectomy, and external-beam radiotherapy.

Racial Disparity Exists in Receipt of High-Quality Prostate Cancer Care

Racial Disparity Exists in Receipt of High-Quality Prostate Cancer Care

By

Despite that most patients with newly diagnosed prostate cancer receive high-quality care, a racial disparity exists, a recent study has shown.

ADT for up to 36 Months Not Associated With Cognitive Decline

ADT for up to 36 Months Not Associated With Cognitive Decline

By

The long-term use of androgen deprivation therapy (ADT) for up to 36 months does not appear to be associated with cognitive decline in patients with prostate cancer.

Incidence of Early Stage Prostate Cancer Lower After USPSTF Recommendation Against PSA Testing

Incidence of Early Stage Prostate Cancer Lower After USPSTF Recommendation Against PSA Testing

By

Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.

Distress Increases Likelihood of Choosing Surgery for Localized Prostate Cancer

Distress Increases Likelihood of Choosing Surgery for Localized Prostate Cancer

By

Emotional distress is associated with an increased likelihood of opting for surgery among men with localized prostate cancer.

Race Does Not Predict Prostate Cancer Metastasis Development

Race Does Not Predict Prostate Cancer Metastasis Development

By

Race is not associated with the development of metastases in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to a recently published study.

Predictors Identified for Switching to Active Treatment in Prostate Cancer

Predictors Identified for Switching to Active Treatment in Prostate Cancer

Ethnicity influences patient decision to pursue active treatment and serial biopsies in active surveillance

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs